Real world evidence of long-term safety and efficacy in patients treated with durvalumab after concurrent chemoradiation for unresectable stage III NSCLC - AYAME

Study identifier:D4194R00013

ClinicalTrials.gov identifier:NCT03995875

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Real world evidence of long-term safety and efficacy in patients treated with durvalumab after concurrent chemoradiation for unresectable stage III NSCLC.

Medical condition

Carcinoma, Non-Small-Cell Lung

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

529

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 25 Jul 2019
Primary Completion Date: 11 Jan 2024
Study Completion Date: 11 Jan 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jan 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

The Japan Lung Cancer Society

Inclusion and exclusion criteria